Derma Sciences Begins Screening Patients in Second Phase 3 Trial with DSC127 for Healing Diabetic Foot Ulcers

Derma Sciences, Inc. (Nasdaq: DSCI ), a medical device and pharmaceutical company focused on advanced wound care, announces that patient screening has begun in the second of two Phase 3 clinical trials with the investigational topical drug candidate DSC127 for the treatment of diabetic foot ulcers. This second trial